Zhejiang Jingxin Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jin Zhiping

İcra Kurulu Başkanı

CN¥1.2m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	11.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jin Zhiping (43 yo)

11.1yrs

Görev süresi

CN¥1,231,400

Tazminat

Mr. Jin Zhiping has been Non-Independent Director of Zhejiang Jingxin Pharmaceutical Co., Ltd. since October 8, 2013 and serves as its President.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jin Zhiping	President & Director	11.1yrs	CN¥1.23m	Veri yok
Chen Meili	VP, CFO & Director	11.1yrs	CN¥957.20k	0.044% CN¥ 4.9m
Yunfei Hong	Secretary of the Board & Non-Independent Director	5.1yrs	CN¥940.20k	Veri yok
Lv Gang	Chairman of the Board	11.1yrs	CN¥1.64m	20.77% CN¥ 2.3b
Wang Nengneng	Vice Chairman	11.1yrs	CN¥1.17m	0.42% CN¥ 46.3m
Tianqing Hu	Chairman of the Supervisory Board	no data	CN¥310.80k	Veri yok
Fen Juan Lin	Employee Representative Member of the Supervisory Board	no data	Veri yok	Veri yok
Pan Xu	Independent Director	2.1yrs	CN¥80.00k	Veri yok
Xiao Jun Xu	Supervisor	5.1yrs	Veri yok	Veri yok
Hu Wan	Non-Independent Director	2.1yrs	CN¥683.40k	Veri yok
Zhang Daliang	Independent Director	2.1yrs	CN¥80.00k	Veri yok
Lei Ying	Independent Director	2.1yrs	CN¥80.00k	Veri yok

5.1yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002020 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Zhejiang Jingxin Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2024

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments

High number of new directors

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 3Q 2023)

Investor sentiment improves as stock rises 21%

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.19 in 2Q 2023)

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.30 announced

Full year 2023 earnings released: EPS: CN¥0.72 (vs CN¥0.77 in FY 2022)

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2024

Investor sentiment deteriorates as stock falls 16%

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan, Payable on 24 May 2023

Full year 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.75 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 2Q 2021)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 25 May 2022

Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves 2021 Profit Distribution Plan At the Annual General Meeting Held on April 22, 2022

High number of new directors

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2022

Full year 2021 earnings released: EPS: CN¥0.75 (vs CN¥0.82 in FY 2020)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces the Final Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.15 in 2Q 2020)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 28, 2021

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.98 (vs CN¥0.73 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.98 (vs CN¥0.73 in FY 2019)

Revenue misses expectations

New 90-day low: CN¥9.20

New 90-day low: CN¥10.52

New 90-day low: CN¥11.21

Third quarter earnings released

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥15.10

Zhejiang Jingxin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 499.999996 million in funding from Jingxin Holding Group Co., Ltd.

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş